EEFECT OF ADJUVANT 904 NM GALLIUM ARSENIDE LASER THERAPY ON HEALING AND BACTERIAL BURDEN IN CHRONIC WOUNDS: A RANDOMIZED CONTROLLED TRIAL.

This is a randomized, double-blind, placebo-controlled clinical trial that evaluated the adjunctive effect of 904 nm Gallium Arsenide (GaAs) laser therapy in the treatment of chronic venous and diabetic ulcers. The study adhered to the CONSORT 2025 guidelines to ensure transparency and quality in reporting. Seventy patients were randomly assigned to two groups: Active Laser Group (AL) (laser + standard care) and Placebo Laser Group (PL) (simulated laser + standard care). All participants were followed twice a week until complete wound healing or a maximum of 15 sessions. Outcomes assessed included wound area reduction, microbial load, and histological analysis. Laser therapy significantly reduced bacterial colonization, particularly of Pseudomonas aeruginosa, Escherichia coli, and Proteus mirabilis (p ≤ 0.007). Histological analysis demonstrated enhanced angiogenesis, reduced inflammatory infiltrate, and improved collagen organization at the wound edges in the AL group (p ≤ 0.042).These findings demonstrated that 904 nm GaAs laser therapy accelerates healing, reduces microbial burden, and promotes favorable tissue remodeling.